It looks as if time to be a Cathy Wooden critic.
I am nonetheless on the fence in regards to the Genomic Bets however have positions in VRTX and REGN (who produce other regular companies and are collaborating with CRISPR and NTLA).
This is the article and an excerpt:
"Wooden can be a cheerleader for this rising subject of medical science, telling CNBC in December that three listed firms within the area — Intellia, Crispr Therapeutics and Editas — characterize a “trillion greenback plus alternative” (though on this occasion she was speaking about their potential mixed market worth, which stands at roughly $12bn, reasonably than income).
The CNBC interview, too, contained statements that might charitably be described as not fairly proper. Wooden mentioned “we’ve already seen useful cures for 3 blood-related illnesses” within the gene enhancing area. No firms have secured regulatory approval for such therapies, nor are they anticipated to any time quickly. Some very early success in medical trials doesn’t a treatment make.
Wooden mentioned Intellia had just lately “introduced a useful treatment” for ATTR amyloidosis, which she described as an “unique blood illness”. ATTR is a protein misfolding dysfunction, not a blood illness, and the corporate is nowhere close to asserting a treatment for it. The trial knowledge she referred to had been derived from simply six sufferers. Intellia is extra cautious in its pronouncements and can solely say its drug “may probably be the primary healing therapy” for the sickness.
Wooden’s breathless promotion of this thrilling however unproved expertise to her large fan base helped gas a biotech bubble in 2020 that burst spectacularly final yr. Her Ark Genomic Revolution fund rode the surge in valuations however is down nearly 60 per cent from its peak in February 2021 and registered roughly $2.5bn of outflows over the identical interval. Her flagship Ark Innovation fund, which additionally holds some gene enhancing shares, has fallen by an identical quantity.”